Efficacy of metreleptin treatment in familial partial lipodystrophy due to PPARG versus LMNA pathogenic variants

Context Familial partial lipodystrophy (FPLD) is most commonly caused by pathogenic variants in LMNA and PPARG. Leptin replacement with metreleptin has largely been studied in the LMNA group.